🤖 OpenAI planning to restructure as For-Profit

Today’s Menu ☕️

🤖 OpenAI Restructuring as For-Profit, Ending Non-Profit Board Control to Attract Investors
📱Xiaomi unveils Xiaomi 14T series with exceptional night photography and advanced AI 
⚕️Pfizer Withdraws Sickle Cell Drug Oxbryta Amid Safety Concerns

If you haven't subscribed, join over 7,000 people curious about Innovation, New Products, New Technologies in Africa.

🤖 ARTIFICIAL INTELLIGENCE

OpenAI Restructuring as For-Profit, Ending Non-Profit Board Control to Attract Investors

OpenAI, the company behind ChatGPT, is reportedly planning a major restructuring of its core business to shift from a non-profit-controlled organization to a for-profit benefit corporation, according to sources familiar with the discussions. This move could make OpenAI more attractive to investors and provide a clearer path for growth, while still keeping a link to its non-profit origins.

The restructuring would involve the OpenAI non-profit retaining a minority stake in the newly structured for-profit entity. However, the for-profit company would no longer be fully governed by the non-profit board. This change has raised questions about how the company will balance its original mission of ensuring safe artificial intelligence (AI) development with its new investor-driven goals...........continue reading

📱GADGETS

Xiaomi 14T Series: Redefining Smartphone Photography with AI-Powered Innovation

Xiaomi has officially launched its newest flagship smartphone series, the Xiaomi 14T Series, which is tailored for photography enthusiasts seeking top-notch imaging features. This new lineup focuses on revolutionizing smartphone photography, with a special emphasis on delivering exceptional night-time shots. Enhanced by cutting-edge AI technology, users of the Xiaomi 14T Series will be able to take clear, vibrant photos in various lighting conditions, day or night.

Alongside impressive performance, the devices also showcase sleek designs, powered by MediaTek processors and vibrant AMOLED displays, making the Xiaomi 14T Series a well-rounded choice for those looking for both aesthetics and performance...…....continue reading

⚕️HEALTH

Pfizer Withdraws Sickle Cell Drug Oxbryta Amid Safety Concerns

US drugmaker, Pfizer has announced the withdrawal of its sickle cell disease treatment, Oxbryta (voxelotor), from all markets where it had been approved. This move comes after concerns emerged about the drug’s safety, specifically an increased risk of serious complications and fatalities.

Pfizer acquired Oxbryta through its $5.4 billion purchase of Global Blood Therapeutics in 2022. The drug, designed to treat sickle cell disease, generated $328 million in revenue for Pfizer in 2023. However, based on recent clinical data, the company concluded that the risks of continuing treatment with Oxbryta outweighed its benefits. As a result, Pfizer is not only halting sales of the drug but also discontinuing all clinical studies and patient access programs related to it.

OXBRYTA, a once-daily oral treatment, was developed to enhance hemoglobin’s oxygen affinity, aiming to prevent the polymerization of sickle hemoglobin..…....continue reading

OTHER STORIES

• Visa to Help Banks Test Tokenized Assets and Smart Contracts….read more

• Google announces 2025 software engineering winter internship….read more

Do you know you can join and follow us with Innovation Village on our WhatsApp Channel?